Overview

Phase 3 Study of ALXN1850 in Pediatric Participants With HPP Previously Treated With Asfotase Alfa

Status:
Recruiting
Trial end date:
2027-10-15
Target enrollment:
Participant gender:
Summary
The primary purpose of this study is to assess the safety and tolerability of ALXN1850 versus asfotase alfa in pediatric participants with HPP previously treated with asfotase alfa.
Phase:
Phase 3
Details
Lead Sponsor:
Alexion Pharmaceuticals, Inc.